First-line immunotherapy in PD-L1-high non-small cell lung cancer: indirect treatment comparison of pembrolizumab and atezolizumab

被引：0
作者：
Griesinger, F. [1 ]
Sibbe, M. S. [2 ]
Hieke-Schulz, S. [2 ]
Buhck, H. [2 ]
Reinmuth, N. [3 ]
Rittmeyer, A. [4 ]
机构：
[1] Pius Hosp Univ Med Oldenburg, Oldenburg, Germany
[2] Roche Pharma AG, Grenzach Wyhlen, Germany
[3] Asklepios Fachkliniken, Munich, Germany
[4] Lungenfachklin Immenhausen, Immenhausen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P448
引用
收藏
页码：227 / 228
页数：2
相关论文
共 50 条
  • [31] Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer
    Zhang, Lei
    Qian, Yijiao
    Li, Jinnan
    Cui, Chenwei
    Chen, Lu
    Qu, Shuli
    Lu, Shun
    FUTURE ONCOLOGY, 2022, 18 (15) : 1896 - 1905
  • [32] First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer
    Travert, Camille
    Tomasini, Pascale
    Jeanson, Arnaud
    Greillier, Laurent
    Barlesi, Fabrice
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (07) : 2514 - 2516
  • [33] Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer
    Shah, Mohsin
    Marmarelis, Melina E.
    Mamtani, Ronac
    Hennessy, Sean
    CLINICAL LUNG CANCER, 2022, 23 (08) : 731 - 736
  • [34] Pemetrexed in first-line treatment of non-small cell lung cancer
    Esteban, Emilio
    Casillas, Marta
    Cassinello, Alejo
    CANCER TREATMENT REVIEWS, 2009, 35 (04) : 364 - 373
  • [35] Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference?
    Bersanelli, Melissa
    Petrelli, Fausto
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S3241 - S3243
  • [36] Real-world data of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression (HOT/NJLCG2001)
    Yokouchi, H.
    Mizugaki, H.
    Ikezawa, Y.
    Morita, R.
    Tateishi, K.
    Yokoo, K.
    Sumi, T.
    Kikuchi, H.
    Nakamura, A.
    Kobayashi, M.
    Aso, M.
    Tsukita, Y.
    Yoshiike, F.
    Furuta, M.
    Tanaka, H.
    Sekikawa, M.
    Hachiya, T.
    Nakamura, K.
    Kitamura, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1574 - S1574
  • [37] Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
    Ryu, Rachel
    Ward, Kristina E.
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [38] Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
    Kenji Morimoto
    Tadaaki Yamada
    Hayato Kawachi
    Motohiro Tamiya
    Yoshiki Negi
    Yasuhiro Goto
    Akira Nakao
    Shinsuke Shiotsu
    Keiko Tanimura
    Takayuki Takeda
    Asuka Okada
    Taishi Harada
    Koji Date
    Yusuke Chihara
    Isao Hasegawa
    Nobuyo Tamiya
    Naoya Nishioka
    Yuki Katayama
    Masahiro Iwasaku
    Shinsaku Tokuda
    Takashi Kijima
    Koichi Takayama
    Targeted Oncology, 2023, 18 : 915 - 925
  • [39] Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer
    Zhou, Yixin
    Zhang, Yaqiong
    Guo, Guifang
    Cai, Xiuyu
    Yu, Hui
    Cai, Yanyu
    Zhang, Bei
    Hong, Shaodong
    Zhang, Li
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 10 (01): : 107 - 115
  • [40] Cost-effectiveness analysis of PD-L1 testing associated with pembrolizumab for first-line treatment of advanced non-small cell lung cancer in China
    Wu, Yao
    Tao, Libo
    Liu, Chang
    Wang, Fangxu
    Sun, Shuang
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2025, : 737 - 746
12345